Loading...
XNASSLS
Market cap76mUSD
Jan 06, Last price  
1.10USD
1D
0.93%
1Q
-14.29%
Jan 2017
-99.96%
IPO
-100.00%
Name

Sellas Life Sciences Group Inc

Chart & Performance

D1W1MN
XNAS:SLS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
154.23%
Rev. gr., 5y
0.00%
Revenues
0k
-100.00%
0000002,038,0002,487,0009,319,000000001,900,0007,600,0001,000,0000
Net income
-37m
L-8.15%
-2,405,000-10,990,000-14,373,000-18,387,000-11,993,000-11,485,000-34,969,000-76,678,000-36,606,000-63,902,000-23,549,000-23,754,000-27,670,000-19,292,000-16,757,000-20,699,000-40,652,000-37,340,000
CFO
-31m
L+31.92%
-2,112,000-6,047,000-9,429,000-11,769,000-10,257,000-14,668,000-20,963,000-28,908,000-42,869,000-48,160,000-44,915,000-10,989,000-30,422,000-17,643,000-10,417,000-26,021,000-23,809,000-31,410,000
Dividend
Dec 09, 20100 USD/sh
Earnings
Mar 26, 2025

Profile

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
URL
https://www.sellaslifesciences.com/
IPO date
Mar 12, 2008
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,000
-86.84%
Cost of revenue
37,869
42,950
Unusual Expense (Income)
NOPBT
(37,869)
(41,950)
NOPBT Margin
Operating Taxes
(649)
Tax Rate
NOPAT
(37,869)
(41,301)
Net income
(37,340)
-8.15%
(40,652)
96.40%
Dividends
Dividend yield
Proceeds from repurchase of equity
22,225
23,994
BB yield
-75.48%
-52.42%
Debt
Debt current
446
372
Long-term debt
1,366
1,518
Deferred revenue
(184)
Other long-term liabilities
4
Net debt
(718)
(15,051)
Cash flow
Cash from operating activities
(31,410)
(23,809)
CAPEX
(4,500)
Cash from investing activities
(5,500)
(4,500)
Cash from financing activities
22,315
24,079
FCF
(27,736)
(41,452)
Balance
Cash
2,530
17,125
Long term investments
(184)
Excess cash
2,530
16,891
Stockholders' equity
(217,241)
(179,902)
Invested Capital
210,171
185,518
ROIC
ROCE
535.63%
EV
Common stock shares outstanding
27,777
19,396
Price
1.06
-55.08%
2.36
-57.32%
Market cap
29,444
-35.68%
45,774
-46.53%
EV
28,726
30,723
EBITDA
(37,869)
(41,493)
EV/EBITDA
Interest
649
Interest/NOPBT